Drug Profile

ETX 394

Alternative Names: ETX-394

Latest Information Update: 06 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator e-Therapeutics
Developer Tangram Therapeutics
Class Amides; Amino sugars; Drug conjugates; Hepatoprotectants; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

06 Nov 2025 Discontinued - Preclinical for Non-alcoholic steatohepatitis in United Kingdom (SC) (Tangram Therapeutics pipeline, November 2025)
01 Oct 2025 e-Therapeutics is now called Tangram Therapeutics
05 Sep 2024 Preclinical trials in Non-alcoholic steatohepatitis in United Kingdom (SC), before September 2024 (e-Therapeutics pipeline, September 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com